Georgieva 2026 — Low-dose IL-2 fails post-alemtuzumab in MS — Q-Gen-7 boundary-defining negative

One-paragraph summary

Pre-clinical + experimental medicine study. Treg expansion is the goal of low-dose IL-2 therapy because Tregs express CD25 (high-affinity IL-2 receptor IL2RA) and are ~10× more IL-2-sensitive than Teffs. Six months after alemtuzumab (lymphocyte-depleting drug for RRMS), frequency of patient-derived naïve CD4+ Teffs expressing high-affinity IL-2 receptors increased from 30.11±5.09% to 72.88±5.57%, and the IL-2-receptor density per cell increased — making Teffs six times more sensitive to IL-2 in vitro at Treg-favoring concentrations. In CD52-transgenic mouse alemtuzumab model, low-dose IL-2 expanded Tregs preferentially ONLY at later time points (corresponding to >6 months post-treatment). Open-label experimental medicine study: low-dose IL-2 at lupus/T1DM dosing (0.3 × 10⁶ IU/m² twice/week) in alemtuzumab-treated RRMS >6 months post-treatment was well-tolerated and safe but failed to expand Tregs. Rule-out analysis excluded sIL2RA neutralization; possible explanations: ceiling effect on Treg proliferation, Treg exhaustion, intrinsic Treg dysfunction in MS. Important boundary-defining negative for Q-Gen-7 (IL2RA / low-dose IL-2 in chronic pain / autoimmune): low-dose IL-2 is not a viable Treg-expansion strategy in immune-reconstitution settings. Sharpens H5/H5b intervention thinking at the Treg-restoration layer.

Claims as triples

• alemtuzumab — increases → high_affinity_IL2_receptor_expression [evidence: 30% → 73% post-treatment; confidence: emerging]
• alemtuzumab_post_treatment — reduces → low_dose_IL2_treg_selectivity [evidence: Teffs become 6× more IL-2-sensitive; confidence: emerging]
• low_dose_IL2 — fails_to_expand → regulatory_T_cell [evidence: experimental medicine open-label in alemtuzumab-treated RRMS; confidence: emerging]
• intrinsic_treg_dysfunction — present_in → multiple_sclerosis [evidence: candidate mechanism; confidence: inferred]
• treg_exhaustion — present_in → multiple_sclerosis [evidence: candidate mechanism; confidence: inferred]

Methods note

Multi-modal: in vitro patient PBMC characterization + CD52-transgenic mouse model + experimental-medicine open-label trial. Strong mechanistic dissection — the in vitro work documents the IL-2-receptor-density shift; the mouse model confirms temporal window; the human trial tests the clinical implementation. Rule-out for sIL2RA neutralization is methodologically clean.

Limitations

• Alemtuzumab-treated population only — generalizability to other autoimmune contexts (or to FM/ME/CFS) is open
• Open-label trial, small experimental-medicine cohort
• Mechanism of failure not fully resolved (ceiling effect vs Treg exhaustion vs intrinsic Treg dysfunction)
• Doesn't test other Treg-expansion strategies (IL-2/anti-IL-2 antibody complexes, IL-2 muteins, low-dose-IL-2 + co-therapy combinations)

Open questions raised

• Q-Gen-21 (new): What Treg-restoration strategies remain candidates for H5/H5b after Georgieva 2026 narrows low-dose-IL-2 standalone? IL-2 muteins (selective IL-2Rα/βγ-biased), low-dose IL-2 + Treg-supportive co-therapies, anti-IL-6 (tocilizumab) for upstream Treg recovery, or direct Treg cellular therapy (TR1-cell adoptive transfer) become alternative arms.
• Q-Gen-22 (new): Is the alemtuzumab-induced IL-2-receptor-density shift on Teffs unique to alemtuzumab, or does it also occur after other immune-reconstitution events? Implications for FM-IgG-positive patients with prior immunosuppressive history or post-viral immune reconstitution.

Triangulation notes

• Boundary-defines Q-Gen-7 (IL2RA / Treg / low-dose IL-2): the H5 cure-path-arm at the Treg-restoration layer cannot use simple low-dose-IL-2 standalone in immune-reconstitution-context patients. The arm remains viable in non-reconstitution FM-IgG-positive patients without recent lymphocyte depletion — but the indication-narrowing is substantial.
• Compatible with MS-FM cross-condition framework: MS is the closest immune-tolerance-failure cross-condition to the FM-autoimmune subtype (via IL2RA + HERV-W + Treg dysfunction shared substrates). The MS-specific Treg dysfunction Georgieva 2026 documents is consistent with the H5/H5b Treg-incompetence layer.
• Sharpens the H5 module IL2_IL21_locus interpretation: IL2/IL21 is in the H5 module not because low-dose IL-2 is a clear cure-path arm but because the locus marks Tfh + germinal-center hyperactivity upstream of FM-IgG production. The cure-path implication is via IL-21 / Tfh-targeted intervention rather than via simple low-dose IL-2.
• Compatible with Bahraini MS SARAF/STIM1/Orai1 paper (same batch): MS Treg dysfunction (Georgieva) + MS SOCE-pathway dysregulation (SARAF paper) both occur in the same disease — possibly the same upstream substrate. The H5b T-cell SOCE arm (Q-IBC-8 T-cell SOCE correlation) gains importance.

Bridges

• Q-Gen-7 boundary-narrowing: bridge framing remains but the intervention is sharpened. Low-dose-IL-2 standalone is excluded for immune-reconstitution-context FM patients; IL-2 muteins or combination approaches remain candidate.

Ontology additions needed

• Consider adding alemtuzumab as new intervention entity (lymphocyte-depleting, immune-reconstitution context)
• Consider adding low_dose_IL2_therapy as intervention entity (refining ontology)
• Consider adding IL2_mutein as intervention entity (alternative arm)
• Consider adding treg_exhaustion and intrinsic_treg_dysfunction as candidate mechanism entities

Chain-map update

• H5/H5b Treg-restoration layer narrowed: simple low-dose-IL-2 standalone in immune-reconstitution-context FM patients is excluded. The Treg-restoration cure-path arm requires either alternative IL-2 formulations or combination approaches.
• Cure-path arm portfolio refinement: H5/H5b intervention break-point #5 (low-dose IL-2 in H5; same in H5b) needs revision in the synthesis docs to specify "non-reconstitution-context patients only" or to point toward alternative IL-2 formulations.

Confidence-tier framing

• Low-dose IL-2 fails to expand Tregs in alemtuzumab-treated RRMS: emerging (experimental medicine small cohort + mechanistic dissection)
• Alemtuzumab-induced IL-2-receptor-density shift on Teffs: emerging
• Intrinsic Treg dysfunction in MS: inferred (candidate mechanism, not directly demonstrated)
• Cross-condition extension to FM Treg-restoration: inferred (predicted by framework)
• Q-Gen-7 boundary-narrowing: applies to immune-reconstitution-context FM patients; non-reconstitution-context unchanged at bridging